...
首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.
【24h】

Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.

机译:根据初始治疗后可检测的血清甲状腺球蛋白水平,接受第二次碘131治疗的分化型甲状腺癌患者的短期结果。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The aim of this study was to evaluate the usefulness of high-dose 131I therapy administered only on the basis of raised serum Tg levels. METHODS: Among patients treated with total or near-total thyroidectomy and 131I ablation, 76 (54 women and 22 men) with differentiated thyroid cancer (41 with follicular and 35 with papillary cancer) showed a detectable (i.e. >1.5 ng/ml) serum Tg level on L: -thyroxine therapy during follow-up and were included in the study. In these patients, a further 131I therapy was scheduled (range 3.7-9.25 GBq, mean 6.087+/-1.705). Five to seven days after this radioiodine therapy, patients underwent 131I post-therapy whole-body scan (131I t-WBS). The serum Tg value at 12 months after 131I therapy was evaluated as an indicator of short-term response to radioiodine. RESULTS: At evaluation after 12 months, 21 (27.6%) of the 76 patients had a Tg value < or =1.5 ng/ml, 12 (15.8%) showed a Tg decrease of at least 50%, 22 (29%) had only a minor decrease in Tg (<50%) and 21 (27.6%) did not show any decrease in Tg. 131I t-WBS was positive in 52 patients (68%, group A) and negative in 24 (32%, group B). Normalisation of Tg was observed in 15 patients (29%) of group A and in six patients (25%) of group B. Overall, 23 (44%) patients of group A and ten (42%) of group B showed a > or =50% decrease in the Tg. Of the 52 patients of group A, 19 (36%) had local recurrence at 131I t-WBS, 18 (35%) showed lung involvement and 15, (29%) bone metastasis. On a patient basis, two (13%) of 15 patients with bone metastases, six (33%) of 18 patients with lung involvement and seven (37%) of 19 patients with local recurrence had Tg values at follow-up of < or =1.5 ng/ml (p NS). Overall, seven (37%) patients with local recurrence, eight (44%) with lung involvement and eight (53%) with bone metastases showed a > or =50% decrease in Tg. CONCLUSION: The findings of the present study suggest that the administration of therapeutic 131I only on the basis of elevated Tg levels has a definite therapeutic effect, at least in the short term. In addition, the possibility of obtaining a post-therapeutic 131I WBS can lead to better strategy definition for these patients.
机译:目的:本研究的目的是评估仅在升高的血清Tg水平的基础上进行的大剂量131I治疗的有效性。方法:在接受全部或几乎全部甲状腺切除术和131I消融治疗的患者中,有76例(54例女性和22例男性)分化型甲状腺癌(41例滤泡性癌和35例乳头状癌)的血清可检测(即> 1.5 ng / ml)随访期间,L:-甲状腺素治疗的Tg水平已纳入研究。在这些患者中,计划进一步的131I治疗(范围3.7-9.25 GBq,平均6.087 +/- 1.705)。放射碘治疗后五到七天,患者接受131I治疗后的全身扫描(131I t-WBS)。 131I治疗后12个月的血清Tg值被评估为对放射性碘短期反应的指标。结果:在12个月后的评估中,76例患者中有21例(27.6%)的Tg值≤1.5 ng / ml,12例(15.8%)的Tg降低了至少50%,22例(29%)的Tg降低了Tg仅略有下降(<50%),而Tg仅下降21(27.6%)。 131 I t-WBS在52例患者中阳性(68%,A组),在24例患者中阴性(32%,B组)。 A组的15名患者(29%)和B组的6名患者(25%)观察到Tg正常。总体而言,A组的23名患者(44%)和B组的10名(42%)显示>或= Tg降低50%。在A组的52例患者中,有19例(36%)在131I t-WBS局部复发,18例(35%)表现为肺受累,15例(29%)骨转移。以患者为基础,在随访中,有15例骨转移患者中有2例(13%),18例肺部受累患者中有6例(33%)和19例局部复发患者中有7例(37%)随访时的Tg值≤ = 1.5 ng / ml(p NS)。总体而言,七名(37%)局部复发患者,八名(44%)肺受累患者和八名(53%)骨转移患者的Tg降低> 50%或= 50%。结论:本研究结果表明,仅在Tg水平升高的基础上,至少在短期内,治疗性131I的给药具有明确的治疗作用。此外,获得治疗后131I WBS的可能性可以为这些患者带来更好的策略定义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号